SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

Overseen by a newly appointed CEO, genetic testing company Invitae will lay off more than 1,000 employees as part of a year-long restructuring plan that’s expected to ultimately save the company ...

SAN FRANCISCO-- (BUSINESS WIRE)-- Invitae Corporation (NYSE:NVTA), a genetic information company, and TME Research, LLC today announced the initiation of a new clinical collaboration to evaluate the ...

The company thinks a post-pandemic world will appreciate the need for genetic information more than before, but Invitae must navigate uncertainty in the meantime. By Maxx Chatsko – May 8, 2020 at ...

-- New sponsored testing program can make it easier for patients to receive genetic testing in Parkinson's disease, early-onset Alzheimer's disease, ALS and other common conditions -- SAN FRANCISCO, ...

SAN FRANCISCO, July 18, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a comprehensive plan to realize the full potential of its industry-leading ...

What is a winner-take-most market? The long term profitability and success of any company is highly dependent on the market in which it operates. Many markets have low barriers to entry; many sellers ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

Last year, Invitae ($NVTA) said that it was aiming to expand its test menu to more than 1,000 genes by mid-2016. Now, the company has achieved that goal ahead of ...

Invitae Corporation NVTA is scheduled to report second-quarter fiscal 2019 results on Aug 6, 2019, after market close. In the first quarter of 2019, the company’s loss per share of 47 cents was wider ...